Article
Targeting IKZF1 via HDAC1: Combating Acute Myeloid Leukemia.
Integrative biology : quantitative biosciences from nano to macro - 23 Jan 2024
Balaji Sathyanarayan, Anbarasu Suvitha, Ramaiah Sudha, Anbarasu Anand
Abstract excerpt
Acute myeloid leukemia (AML) accounts for 1.3% of all cancers, with a limited survival of only 30%, and treating AML is a continuous challenge in medicine. IKZF1 is a DNA-binding protein that is highly mutated and undruggable but significant in causing AML. The current study aims to target its transcription factors (TFs) modulating IKZF1 activity. The TF network was constructed and analyzed which revealed a dense...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
